Rapamycin suppresses postnatal muscle hypertrophy induced by myostatin-inhibition accompanied by transcriptional suppression of the Akt/mTOR pathway
Myostatin (MSTN) is a well-known negative growth factor of muscle mass, and studies have shown that MSTN-inhibition would be a potential strategy to treat muscle atrophy seen in various clinical conditions. Recent studies suggest that MSTN-inhibition induces skeletal muscle hypertrophy through up-re...
Main Authors: | Dong hyuck Choi, Jinzeng Yang, Yong Soo Kim |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2019-03-01
|
Series: | Biochemistry and Biophysics Reports |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2405580818302103 |
Similar Items
-
Effects of Chronic Akt/mTOR Inhibition by Rapamycin on Mechanical Overload–Induced Hypertrophy and Myosin Heavy Chain Transition in Masseter Muscle
by: Daisuke Umeki, et al.
Published: (2013-01-01) -
Lysophosphatidic Acid Is Associated With Cardiac Dysfunction and Hypertrophy by Suppressing Autophagy via the LPA3/AKT/mTOR Pathway
by: Jinjing Yang, et al.
Published: (2018-09-01) -
Denervation atrophy is independent from Akt and mTOR activation and is not rescued by myostatin inhibition
by: Elizabeth M. MacDonald, et al.
Published: (2014-04-01) -
Hypertrophy of Rat Skeletal Muscle Is Associated with Increased SIRT1/Akt/mTOR/S6 and Suppressed Sestrin2/SIRT3/FOXO1 Levels
by: Zoltan Gombos, et al.
Published: (2021-07-01) -
Hedyotis diffusa Willd. Suppresses Hepatocellular Carcinoma via Downregulating AKT/mTOR Pathways
by: Lingli Huang, et al.
Published: (2021-01-01)